NASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis $1.06 -0.06 (-5.36%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.05 -0.01 (-1.32%) As of 11/20/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Equillium Stock (NASDAQ:EQ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Equillium alerts:Sign Up Key Stats Today's Range$1.06▼$1.1750-Day Range$1.06▼$2.1052-Week Range$0.81▼$3.54Volume567,888 shsAverage Volume341,783 shsMarket Capitalization$87.26 millionP/E RatioN/ADividend YieldN/APrice Target$7.13Consensus RatingModerate Buy Company Overview Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs. The company’s leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand. Biocon has separately marketed the medicine in India. Equillium has also pursued other immunology programs, including investigational therapies designed to modulate cytokine signaling. These programs and product candidates are in development and are not necessarily approved or available for sale.AI Generated. May Contain Errors. Read More Equillium Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreEQ MarketRank™: 2.20227240847 of 5 starsEquillium scored higher than 44% of companies evaluated by MarketBeat, and ranked 555th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingEquillium has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEquillium has a consensus price target of $7.13, representing about 572.2% upside from its current price of $1.06.Amount of Analyst CoverageEquillium has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Equillium's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from ($0.19) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.37% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 9.52.Change versus previous monthShort interest in Equillium has recently increased by 4.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.13 News SentimentEquillium has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Equillium this week, compared to 2 articles on an average week.Search Interest9 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have not sold or bought any company stock.Percentage Held by Insiders17.84% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.05% of the stock of Equillium is held by institutions.Read more about Equillium's insider trading history. Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EQ Stock News HeadlinesReviewing Oncobiologics (NASDAQ:OTLK) and Equillium (NASDAQ:EQ)November 17, 2026 | americanbankingnews.comEquillium Q3 Loss Widens On Higher R&D ExpensesNovember 14, 2026 | rttnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 22 at 1:00 AM | Paradigm Press (Ad)Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMEquillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical HighlightsNovember 12, 2026 | globenewswire.comEquillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504October 26, 2026 | globenewswire.comEquillium, Inc. Receives Australian Regulatory Clearance to Initiate First-In-Human Clinical Trial of Eq504October 7, 2026 | marketscreener.comMEquillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26October 7, 2026 | rttnews.comSee More Headlines EQ Stock Analysis - Frequently Asked Questions How have EQ shares performed this year? Equillium's stock was trading at $1.55 at the start of the year. Since then, EQ shares have decreased by 31.6% and is now trading at $1.06. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. When did Equillium IPO? Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,670,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO. Who are Equillium's major shareholders? Top institutional investors of Equillium include Aberdeen Group plc (7.03%), RA Capital Management L.P. (3.66%), Marshall Wace LLP (1.18%) and State Street Corp (0.31%). Insiders that own company stock include Stephen Connelly, Penny Tom and Christine Zedelmayer. View institutional ownership trends. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Equillium own? Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include Inovio Pharmaceuticals (INO), AMC Entertainment (AMC), NIO (NIO), Pfizer (PFE), Block (XYZ), Micron Technology (MU) and NVIDIA (NVDA). Company Calendar Last Earnings11/12/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EQ's financial health is in the Yellow zone, according to TradeSmith. EQ has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EQ CIK1746466 Webequilliumbio.com Phone(858) 412-5302FaxN/AEmployees14Year Founded2017Price Target and Rating Average Price Target for Equillium$7.13 High Price Target$12.00 Low Price Target$4.00 Potential Upside/Downside+572.2%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.33% Return on Assets-35.07% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.66Miscellaneous Outstanding Shares82,325,000Free Float67,638,000Market Cap$87.26 million OptionableOptionable Beta2.08 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:EQ) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.